Vinay Prasad to head FDA division regulating vaccines
Source: SeekingAlpha
2025-05-06 14:30:15 ET
More on BioNTech, Moderna, etc.
- BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade)
- BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript
- BioNTech SE 2025 Q1 - Results - Earnings Call Presentation
- Pfizer, GSK RSV shot recommendations under scrutiny from RFK Jr. aide - report
- SA analyst downgrades: COP, ON, BNTX, SKX, ALIZY, SFM
Read the full article on Seeking Alpha
For further details see:
Vinay Prasad to head FDA division regulating vaccines
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-4.98% G/L:
$56.52 Last:
259,831 Volume:
$58.62 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
